Fate Therapeutics

FATE Micro Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$1.22

-1.61% today

52W: $0.68 – $1.94

52W Low: $0.68 Position: 42.9% 52W High: $1.94

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

21.34x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$141.8M

Market Capitalization

Revenue Growth

-26.4%

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-51.84%

Return on Equity

Beta

2.24

Market sensitivity

Short Interest

9.13%

% of float sold short

Avg. Volume

1,636,370

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

None

9 analysts

Avg. Price Target

$4.94

+305.28% upside

Target Range

$2.00 – $8.00

About the Company

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT836 which is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, FT839, to treat complex autoimmune diseases; and FT825 to treat solid tumors. It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. The company was incorporated i

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 161 Exchange: NGM